Death after ST-elevation myocardial infarction in patients treated with fibrinolytic therapy, angioplasty, or conventional therapy. A post-mortem study to verify cardiac rupture as a cause of death;Studio autoptico in pazienti con infarto miocardico associate a sopraslivellamento del tratto ST trattati con fibrinolisi, angioplastica o terapia convenzionale indirizzato alia ricerca della rottura di cuore quale causa di exitus

Giornale Italiano di Cardiologia

Volumn 9, Issue 6, 2008, Pages 408-420

  Fornaro, Gianluigi ^a   Lazzero, Maurizio ^a   Giacalone, Angela ^b   Aralda, Donatella ^a   Prando, Maria Domenica ^a   Rossi, Lidia ^a   Bongo, Angelo Sante ^a  

^a Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

^b Istituto di Anatomia Patologica   (Italy)

Author keywords

Cardiac rupture; Coronary angioplasty; Therapy

Indexed keywords

FIBRINOLYTIC AGENT;

AGED; ARTICLE; AUTOPSY; CARDIOGENIC SHOCK; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEART DEATH; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART RUPTURE; HISTOPATHOLOGY; HUMAN; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; REPERFUSION INJURY; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CAUSE OF DEATH; ELECTROCARDIOGRAPHY; FEMALE; HEART RUPTURE, POST-INFARCTION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 48249154603     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Assessment of the Safety and Efficacy of a New Thrombolytic regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
2. Askari AT, Lincoff AM. GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries. Cleve Clin J Med 2002; 69: 554-60.
3. Di Chiara A, Chiarella F, Savonitto S, et al, for the BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24: 1616-29.
4. Steffenino G, Chinaglia A, Millesimo G, Orlando A, Gnavi R. L'assistenza all'infarto miocardico acuto in Piemonte: risultati del Registro PRIMA. http://www.dors.it/alleg/0201/Registo_PRIMA_01_2006.pdf.
5. Gruppo Italiano per lo Studio delta Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
8. The Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
9. Mauri F, De Biase AM, Franzosi MG, Pampallona S, Foresti A, Gasparini M. GISSI: analisi delle cause di morte intraospedaliera. G Ital Cardiol 1987; 17: 37-44.
10. Honan MB, Harrell FE Jr, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990; 16: 359-67.
11. Loukinen KL, O'Neill W, Laufer N, Lew A, Timmis GC. Myocardial rupture complicating tissue plasminogen activator therapy for acute myocardial infarction [abstract]. J Am Coll Cardiol 1983; 13: 94A.
12. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985; 76: 1713-9.
13. Reperfusion injury after thrombolytic therapy for acute myocardial infarction. Lancet 1989; 2: 655-7.
14. Baigent C. Cardiologia invasiva. In: Atti XI Corso di Emodinamica e Cineangioterapia e Angiografia. 1993: 91-103.
15. Becker AE, van Mantgem JP. Cardiac tamponade. A study of 50 hearts. Eur J Cardiol 1975; 3: 349-58.
16. Shapira I, Isakov A, Burke M, Almog C. Cardiac rupture in patients with acute myocardial infarction. Chest 1987; 92: 219-23.
17. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7: 717-28.
18. Hutchins KD, Skurnick J, Lavenhar M, Natarajan GA. Cardiac rupture in acute myocardial infarction: a reassessment. Am J Forensic Med Pathol 2002; 23: 78-82.
19. Sakai T, Inoue S, Murakami M, et al. Clinicopathological study of left ventricular remodeling after first acute myocardial infarction. J Cardiol 2000; 35: 325-34.
20. Kawano H, Miyauchi K, Okada R, et al. Histopathological study of cardiac rupture following myocardial infarction with and without thrombolytic therapy. J Cardiol 1994; 24: 249-55.
21. Sobkowicz B, Lenartowska L, Nowak M, et al. Trends in the incidence of the free wall cardiac rupture in acute myocardial infarction. Observational study: experience of a single center. Rocz Akad Med Bialymst 2005; 50: 161-5.
22. Mottura G. Tecnica delle autopsie per riscontro diagnostico. Torino: UTET, 1963.
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
24. Williams DO, Braunwald E, Knatterud G, et al. One-year results of the Thrombolysis in Myocardial Infarction Investigation (TIMI) Phase II Trial. Circulation 1992; 85: 533-42.
25. Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993; 22: 1763-72.
26. Kleiman NS, Terrin M, Mueller H, et al. Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. J Am Coll Cardiol 1992; 19: 1129-35.
27. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-14.
28. Kleiman NS, White HD, Ohman EM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation 1994; 90: 2658-65.
29. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-9.
30. Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction. A meta-analysis. Circulation 1993; 88: 2575-81.
31. Lautsch EV, Lanks KW. Pathogenesis of cardiac rupture. Arch Pathol 1967; 84: 264-71.
32. Batts KP, Ackermann DM, Edwards WD. Postinfarction rupture of the left ventricular free wall: clinicopathologic correlates in 100 consecutive autopsy cases. Hum Pathol 1990; 21: 530-5.
33. Gertz SD, Kragel AH, Kalan JM, Braunwald E, Roberts WC. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Am J Cardiol 1990; 66: 904-9.
34. Fujiwara H, Onodera T, Tanaka M, et al. A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase. Circulation 1986; 73: 749-57.
35. Waller BF. The pathology of acute myocardial infarction: definition, location, pathogenesis, effects of reperfusion, complications, and sequelae. Cardiol Clin 1988; 6: 1-28.
36. Yasuno M, Endo S, Takahashi M, et al. Angiographic and pathologic evidence of hemorrhage into the myocardium after coronary reperfusion. Angiology 1984; 35: 797-801.
37. Richardson SG, Allen DC, Morton P, Murtagh JG, Scott ME, O'Keeffe DB. Pathological changes after intravenous streptokinase treatment in eight patients with acute myocardial infarction. Br Heart J 1989; 61: 390-5.
38. Higginson LA, White F, Heggtveit HA, Sanders TM, Bloor CM, Covell JW. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation 1982; 65: 62-9.
39. Gertz SD, Kalan JM, Kragel AH, Roberts WC, Braunwald E. Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. Am J Cardiol 1990; 65: 953-61.
40. Factor SM, Robinson TF, Dominitz R, Cho SH. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. A preliminary report. Am J Cardiovasc Pathol 1986; 1: 91-7.
41. Campbell SE, Diaz-Arias AA, Weber KT. Ventricular rupture and fibrillar collagen degradation [abstract]. Circulation 1991; 84 (Suppl II): II-232.
42. Schaper J, Schaper W. Reperfusion of ischemic myocardium: ultrastructural and histochemical aspects. J Am Coll Cardiol 1983; 1: 1037-46.
43. Bulkely BH, Hutchins GM. Myocardial consequences of coronary artery bypass graft surgery. The paradox of necrosis in areas of revascularization. Circulation 1977; 56: 906-13.
44. Becker LC, Ambrosio G. Myocardial consequences of reperfusion. Prog Cardiovasc Dis 1987; 30: 23-44.
45. Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation 1985; 72: 18-20.
46. Pepine CJ, Prida X, Hill JA, Feldman RL, Conti CR. Percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am Heart J 1984; 107: 820-2.
47. Guarnieri C, Flamigni F, Caldarera CM. Role of oxygen in the cellular damage induced by re-oxygenation in hypoxic heart. J Mol Cell Cardiol 1980; 12: 797-808.
48. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-508.
49. Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J 1999; 138 (2 Pt 2): S69-S75.
50. Chatelain P, Latour JG, Tran D, de Lorgeril M, Dupras G, Bourassa M. Neutrophil accumulation in experimental myocardial infarcts: relation with extent of injury and effect of reperfusion. Circulation 1987; 75: 1083-90.
51. Feinberg H, Rosenbaum DS, Levitsky S, Silverman NA, Kohler J, LeBreton G. Platelet deposition after surgically induced myocardial ischemia. An etiologic factor for reperfusion injury. J Thorac Cardiovasc Surg 1982; 84: 815-22.
52. Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML. Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. Circulation 1986; 74: 1424-33.
53. Villari B, Ambrosio G, Golino P, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993; 125: 11-23.
54. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989; 80: 1846-61.
55. 2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001; 280: H2649-H2657.
56. Charney RH, Takahashi S, Zhao M, Sonnenblick EH, Eng C. Collagen loss in the stunned myocardium. Circulation 1992; 85: 1483-90.
57. Whittaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial infarct expansion. Circulation 1991; 84: 2123-34.
58. Peuhkurinen KJ, Risteli L, Melkko JT, Linnaluoto M, Jounela A, Risteli J. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991; 83: 1969-75.
59. Dreyer WJ, Michael LH, West MS, et al. Neutrophil accumulation in ischemic canine myocardium, nsights into time course, distribution, and mechanism of localization during early reperfusion. Circulation 1991; 84: 400-11.
60. Farb A, Kolodgie FD, Jenkins M, Virmani R. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J Am Coll Cardiol 1993; 21: 1245-53.
61. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol 1996; 27: 1321-6.